biologic

Oxervate

cenegermin-bkbj

Loss of exclusivityAugust 2030projected — 12-year biologic exclusivity estimate
CompanyDompé farmaceutici S.p.A.

Drug detail

Brand nameOxervate
Active ingredientcenegermin-bkbj
Strength0.002% (20MCG/ML)
Dosage formSolution
RouteTopical
ModalityBiologic
FDA approvalAugust 2018
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Oxervate patent cliff — loss of exclusivity August 2030 | CliffBio